This is a routine initial filing for a key affiliate of a major shareholder. No immediate trading signal, but highlights continued institutional backing ahead of a potential IPO. Monitor for future changes in voting power or dispositions.
Price Chart
Executive Summary
Adam Koppel, a Partner at Bain Capital Life Sciences Investors, filed a Form 3 disclosing indirect beneficial ownership of 21,020,768 shares of Kailera Therapeutics common stock through his affiliation with BCLS Fund IV Investments, LP. The shares consist of 16,875,000 shares underlying Series A-1 Preferred Stock and 4,145,768 shares underlying Series B Preferred Stock, both convertible on a 1:1 basis into common stock.
Key Facts
- Adam Koppel filed an initial Form 3 as a beneficial owner.
- He is deemed to share voting and dispositive power over securities held by BCLS Fund IV Investments, LP due to his role at Bain Capital Life Sciences Investors.
- The filing reports indirect ownership of 16,875,000 shares of common stock via Series A-1 Preferred Stock and 4,145,768 shares via Series B Preferred Stock.
- Both preferred stock classes are convertible into common stock on a 1:1 basis, automatically upon IPO.
- Koppel disclaims beneficial ownership except to the extent of his pecuniary interest.
Financial Impact
No direct financial impact; reflects passive institutional ownership structure.
Risk Factors
- Potential for future dilution upon conversion of preferred shares.
- Concentration of ownership among insiders may limit float and trading liquidity post-IPO.
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 3 Filing (Primary) | 0001193125-26-159772 |
| Document: 0001193125-26-159772-index.html | 0001193125-26-159772 |
| Document: 0001193125-26-159772.txt | 0001193125-26-159772 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 9, 2026 22d ago | 3 | $14.91 $12.92 | ▼ −13.35% | ▼ −12.85% | $10.39 (−30.32%) |
Aug 12, 2026 7w ago | 8-K | $17.97 $17.47 | ▼ −2.78% | ▼ −0.82% | $10.39 (−42.18%) |
Jul 31, 2026 9w ago | Court Ruling | $16.94 $18.66 | ▲ +10.15% | ▲ +6.64% | $10.39 (−38.67%) |
Jul 24, 2026 10w ago | Court Ruling | $17.69 $17.05 | ▼ −3.62% | ▼ −3.99% | $10.39 (−41.27%) |
Jun 5, 2026 16w ago | Press Release | $19.70 $19.67 | ▼ −0.15% | ▼ −2.26% | $10.39 (−47.26%) |
May 26, 2026 18w ago | 8-K | $21.91 $22.38 | ▲ +2.15% | ▲ +1.68% | $10.39 (−52.58%) |
May 26, 2026 18w ago | Press Release | $21.91 $22.59 | ▲ +3.10% | ▲ +1.90% | $10.39 (−52.58%) |
May 13, 2026 20w ago | Press Release | $21.11 $19.62 | ▼ −7.06% | ▼ −5.90% | $10.39 (−50.78%) |
Apr 20, 2026 23w ago | 8-K | $25.22 $23.82 | ▼ −5.55% | ▼ −6.63% | $10.39 (−58.80%) |
Apr 20, 2026 23w ago | Insider Cluster | $24.61 $23.51 | ▼ −4.47% | ▼ −5.38% | $10.39 (−57.78%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access